Resveratrol player faces bankruptcy if omega-3 funding switch fails: Chairman


- Last updated on GMT

Related tags Venture capital

Fluxome is hoping fresh investment will avert the road to bankruptcy...
Fluxome is hoping fresh investment will avert the road to bankruptcy...
Global resveratrol player Fluxome has 8-12 weeks to raise millions of euros to fund a research switch to omega-3, or face bankruptcy, its chairman told NutraIngredients this morning.

Jarne Elleholm said, contrary to rumours, the company had not filed for bankruptcy although it faced a serious “funding crisis”​ that could end that way if one of 3-4 potential investors did not back its planned shift into omega-3s sourced from yeast.

“We are speaking with 3-4 interested parties including industry players and capital funds and expect to have a clear picture on how to move forward in 8-12 weeks,” ​Elleholm said, noting the figure required was in the seven-figure range.

If the funding failed to eventuate, the company – both its Danish and US operations – faced bankruptcy unless a buy-out partner arose or funding could be found internally.

In the meantime Fluxome filed for “formal reconstruction”​ in Danish courts last week which again is expected to take 8-12 weeks to resolve. 

Its Danish office is closed while the reconstruction takes place, but Elleholm emphasised that resveratrol supply in the US was "business as usual". 

Elleholm said the resveratrol business was moving steadily ahead in the US, but obviously its performance is not strong enough to have averted the current dilemmas for the company.

“There is an issue and we are managing it in an appropriate way to make ends meet and get the required funding,” ​Elleholm said.

Fluxome is owned by venture capital firms based in Belgium, France and Denmark.

Related news

Show more

Related products

show more

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 08-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Sweetening solution for active nutrition

Sweetening solution for active nutrition

Content provided by ADM | 19-Feb-2024 | Case Study

When you add GrainSweet® Liquid Maltodextrin to your active nutrition applications, you get the production efficiencies, clean labels, and clean tastes...

Nutritional Solutions for Women's Health

Nutritional Solutions for Women's Health

Content provided by INNOBIO Corporation Limited | 04-Oct-2023 | White Paper

INNOBIO provides innovative solutions for women to overcome a variety of health challenges throughout the life cycle, from emotional health, PMS management,...

Related suppliers


Show more

Why is this news?

Posted by James,

Another poorly run company is going out of business. Why is this news? When you tie your business model to a single product that has no immediate usefulness to the average consumer you are asking for trouble.

Report abuse

Biotivia's dosage conclusion

Posted by James Betz,

Biotivia has collaborated with more research organisations on more human clinical trials than all other brands combined. We understand dosage, better I submit, than other manufacturers. Based upon the results of trials done using Bioforte and transmax at Northumbria Univ, Ottawa Hospital (A Health Canada hospital) the National Health Service in the UK, Univ. of Ferrara, Harvard, University of Bologna, the NIH, several health ministries in the EU, The Australian National Health Service (Prince Albert Hosp.) and many others, it is our informed conclusion that the appropriate chemo protective dosage for a 75kg man or woman is between 125mg and 2500mg daily.

The efficacy of RSV is certainly dose dependent and seems to follow a relatively linear progression. To suggest that a dosage of 10mg or anything under a 100mg daily is optimum is simply an uninformed and irresponsible misrepresentation of the evidence.

Report abuse

Resveratrol dosage

Posted by Laszlo G Meszaros,

We have completed a clinical trial on the effects of resveratrol on type 2 diabetes (one might be able to find this study on PubMed). From this and another ongoing study on flow-mediated vasodilation, it seems that the optimal resveratrol dosage is about 2x10 mg daily...

Report abuse

Follow us


View more